Cambridge

AstraZeneca subsidiary MedImmune Inc opened a new biologics research and development centre in Cambridge, UK, a major expansion to its base at the former Cambridge Antibody Technology facility.

Planning permission has been granted for the development of 70 acres of land next to Addenbrooke’s Hospital on the southern fringe of Cambridge to provide 2.3 million sq ft of biomedical research and development facilities.

The universities of Cambridge and Manchester, Imperial College London and the SETsquared Partnership, a joint venture among four universities in southern England, have won funding to collaborate with peers in the US and with companies such as Airbus and Boeing.